{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:45:18Z","timestamp":1790207118081,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009045","name":"Uniwersytet Jagiello\u0144ski Collegium Medicum","doi-asserted-by":"publisher","award":["N43\/DBS\/000099"],"award-info":[{"award-number":["N43\/DBS\/000099"]}],"id":[{"id":"10.13039\/100009045","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Polish Association Supporting People with Inflammatory Bowel Disease \u201cJ-elita\u201d"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There is a high variability of out-of-packet patient costs of inflammatory bowel diseases (IBDs), but the issue is not widely recognised. Therefore, we compared patient costs of IBDs between 12 European countries.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A questionnaire-based study was conducted among adult patients with IBD. Data on patient characteristics and out-of-pocket expenses were anonymously collected. Ordered logit regression models were used to analyse the responses provided by patients. The results were adjusted for confounders and multiplicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The questionnaires obtained from 3687 patients were analysed. Patients with comorbidities and active disease indicated higher out-of-pocket expenses than those without comorbidities and with disease in remission, respectively. Compared with other IBD, patients with ulcerative colitis indicated higher expenses on medications prescribed or recommended by physicians [odds ratio (OR) 1.99, 95% CI 1.48\u20132.67]. Expenses on dietary supplements, special diet or equipment, ostomy pouches, and transportation to a medical facility differed slightly between patients at different ages and were lower among men than among women (OR 0.71, 95% CI 0.54\u20130.93). The expenses differed significantly between countries. An adjusted mean patient cost per month varied from \u20ac77 (patient with Crohn disease in remission from Denmark) to \u20ac376 (patient with active ulcerative colitis from Romania). Compared with active disease, patients with IBD in remission had a lower out-of-pocket cost by 29\u201362% (\u20ac10\u2013\u20ac22 monthly; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The study revealed a high relevance of the out-of-pocket cost of IBD in the context of economic evaluation and a high variability of the cost between countries.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10198-022-01536-9","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T16:02:45Z","timestamp":1666195365000},"page":"1073-1083","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Out-of-pocket expenses of patients with inflammatory bowel disease: a comparison of patient-reported outcomes across 12 European countries"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6821-4078","authenticated-orcid":false,"given":"Przemys\u0142aw","family":"Holko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Kawalec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Sajak-Szczerba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Avedano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Mossakowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"key":"1536_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3899\/jrheum.110901","volume":"88","author":"P Jacobs","year":"2011","unstructured":"Jacobs, P., Bissonnette, R., Guenther, L.C.: Socioeconomic burden of immune-mediated inflammatory diseases\u2013focusing on work productivity and disability. J. Rheumatol. Suppl. 88, 55\u201361 (2011)","journal-title":"J. Rheumatol. Suppl."},{"issue":"3","key":"1536_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/apt.16445","volume":"54","author":"RCA van Linschoten","year":"2021","unstructured":"van Linschoten, R.C.A., Visser, E., Niehot, C.D., van der Woude, C.J., Hazelzet, J.A., van Noord, D., West, R.L.: Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Aliment Pharmacol. Ther. 54(3), 234\u2013248 (2021)","journal-title":"Aliment Pharmacol. Ther."},{"key":"1536_CR3","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1097\/MCG.0b013e31828b2196","volume":"47","author":"F Bennebroek Evertsz'","year":"2013","unstructured":"Bennebroek Evertsz\u2019, F., Hoeks, C.C., Nieuwkerk, P.T., Stokkers, P.C., Ponsioen, C.Y., Bockting, C.L., Sanderman, R., Sprangers, M.A.: Development of the patient Harvey Bradshaw index and a comparison with a clinician-based Harvey Bradshaw index assessment of Crohn\u2019s disease activity. J. Clin. Gastroenterol. 47, 850\u2013856 (2013)","journal-title":"J. Clin. Gastroenterol."},{"key":"1536_CR4","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.crohns.2012.11.007","volume":"7","author":"F Bennebroek Evertsz'","year":"2013","unstructured":"Bennebroek Evertsz\u2019, F., Nieuwkerk, P.T., Stokkers, P.C.F., et al.: The Patient Simple Clinical Colitis Activity Index (P-SCCAI) can detect ulcerative colitis (UC) disease activity in remission: a comparison of the P-SCCAI with clinician-based SCCAI and biological markers. J. Crohns Colitis. 7, 890\u2013900 (2013)","journal-title":"J. Crohns Colitis."},{"key":"1536_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac144","author":"P Holko","year":"2022","unstructured":"Holko, P., Kawalec, P., Sajak-Szczerba, M., Avedano, L., Mossakowska, M.: Indirect costs of inflammatory bowel diseases: a comparison of patient-reported outcomes across 12 European countries. Inflamm Bowel Dis (2022). https:\/\/doi.org\/10.1093\/ibd\/izac144","journal-title":"Inflamm Bowel Dis"},{"key":"1536_CR6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., G\u00f8tzsche, P.C., Vandenbroucke, J.P.: The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J. Clin. Epidemiol. 61, 344\u2013349 (2008)","journal-title":"J. Clin. Epidemiol."},{"issue":"6","key":"1536_CR7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/ibd\/izaa167","volume":"27","author":"M Attauabi","year":"2021","unstructured":"Attauabi, M., Zhao, M., Bendtsen, F., Burisch, J.: Systematic review with meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease course of inflammatory bowel diseases. Inflamm. Bowel Dis. 27(6), 927\u2013939 (2021)","journal-title":"Inflamm. Bowel Dis."},{"key":"1536_CR8","unstructured":"EUROSTAT. Health care (hlth_care) [Data file]. Retrieved from https:\/\/ec.europa.eu\/eurostat\/web\/main\/data\/database (2022). Accessed 29 July 2022"},{"key":"1536_CR9","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1136\/gut.2004.041616","volume":"53","author":"A Bassi","year":"2004","unstructured":"Bassi, A., Dodd, S., Williamson, P., Bodger, K.: Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 53, 1471\u20131478 (2004)","journal-title":"Gut"},{"issue":"12","key":"1536_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168586","volume":"11","author":"P Holko","year":"2016","unstructured":"Holko, P., Kawalec, P., Mossakowska, M., Pilc, A.: Health-related quality of life impairment and indirect cost of Crohn\u2019s disease: a self-report study in Poland. PLoS ONE 11(12), e0168586 (2016)","journal-title":"PLoS ONE"},{"key":"1536_CR11","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.dld.2003.07.002","volume":"35","author":"J Juan","year":"2003","unstructured":"Juan, J., Estiarte, R., Colome, E., Art\u00e9s, M., Jim\u00e9nez, F.J., Alonso, J.: Burden of illness of Crohn\u2019s disease in Spain. Dig. Liver Dis. 35, 853\u2013861 (2003)","journal-title":"Dig. Liver Dis."},{"key":"1536_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40258-016-0272-z","volume":"15","author":"M Kostic","year":"2017","unstructured":"Kostic, M., Djakovic, L., Sujic, R., Godman, B., Jankovic, S.M.: Inflammatory bowel diseases (Crohn s disease and ulcerative colitis): cost of treatment in Serbia and the implications. Appl. Health Econ. Health Policy. 15, 85\u201393 (2017)","journal-title":"Appl. Health Econ. Health Policy."},{"key":"1536_CR13","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1002\/ibd.20939","volume":"15","author":"J Mesterton","year":"2009","unstructured":"Mesterton, J., Jonsson, L., Almer, S.H., Befrits, R., Friis-Liby, I., Lindgren, S.: Resource use and societal costs for Crohn\u2019s disease in Sweden. Inflamm. Bowel Dis. 15, 1882\u20131890 (2009)","journal-title":"Inflamm. Bowel Dis."},{"key":"1536_CR14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2165\/00019053-200624080-00006","volume":"24","author":"R Stark","year":"2006","unstructured":"Stark, R., K\u00f6nig, H.H., Leidl, R.: Costs of inflammatory bowel disease in Germany. Pharmacoeconomics 24, 797\u2013814 (2006)","journal-title":"Pharmacoeconomics"},{"key":"1536_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","volume":"63","author":"ME van der Valk","year":"2014","unstructured":"van der Valk, M.E., Mangen, M.J., Leenders, M., Dijkstra, G., van Bodegraven, A.A., Fidder, H.H., et al.: Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: results from the COIN study. Gut 63, 72\u201379 (2014)","journal-title":"Gut"},{"key":"1536_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142481","volume":"11","author":"ME van der Valk","year":"2016","unstructured":"van der Valk, M.E., Mangen, M.-J., Severs, M., et al.: Evolution of costs of inflammatory bowel disease over two years of follow-up. PLoS ONE 11, e0142481 (2016)","journal-title":"PLoS ONE"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-022-01536-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-022-01536-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-022-01536-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T14:07:57Z","timestamp":1691417277000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-022-01536-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1536"],"URL":"https:\/\/doi.org\/10.1007\/s10198-022-01536-9","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,19]]},"assertion":[{"value":"4 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}